Clinical information
Clinical utility
Hematopoietic progenitor cell (HPC) mobilisation and collection from peripheral blood is currently the most widely used source of cells for hematopoietic progenitor cell transplantation (HPCT) in adult patients.
Method
Granulocyte colony-stimulating factor (G-CSF) is the most frequently used agent for HPC mobilisation. Mobilisation combining chemotherapy and G-CSF is significantly more effective in autologous mobilisation.
Using a cell separator that centrifuges the blood, the cellular components are separated according to their density and the device collects the mononuclear cells in which the HPCs are found.
Reference values
The minimum number of HPC to be collected to perform an autologous HPCT is 2E6 CD34/kg and 4E6 CD34/kg in the case of an allogeneic HPCT.
Specimen information
Product: mobilised HPCs *anticoagulants* with 10% ACDA.
Tube: EDTA tube of peripheral blood (control sample).
Volume: maximum volume of 1 litre.
Shelf life: 72 hours.
Transport instructions: between 2 and 22 °C.
Storage instructions: between 2 and 8 °C.
Administrative information
BST code: BT201 and BT202.
Description of the test: HPC collection by apheresis with controls.
Synonyms: HPC-A.
Section: Regional Blood and Tissue Bank (BST) Apheresis Unit.
Service: fee BT201 includes donor screening and the analytical tests necessary for their evaluation, extraction of the cells with an apheresis machine and transport to the cell processing laboratory. Fee BT202 is applied if the collection centre performs analytical controls on the collected product (cell or progenitor cell count).
References
Areman, E. M.; Loper, K., editors. Cellular therapy: Principles, methods, and regulations. 2nd ed. Bethesda (MD): AABB Press, 2016.
Quality
The BST has ISO 9001, ISO 14001, OSHAS 18001 and European Seal of Excellence 500+ quality certifications. The BST is accredited by CAT, JACIE-FACT, FACT-NETCORD and EFI. It complies with the guidelines of good manufacturing and good distribution practices.
